Among patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to treatment with second-generation tyrosine kinase inhibitors (TKIs), the third-generation TKI ponatinib offers improved treatment response and survival, according to an analysis of two open-label, phase 2 trials (Am J Hematol 2022 Aug 12. doi.org/10.1002/ajh.26686).
The pivotal phase 2 PACE trial enrolled patients who were resistant to second-generation TKIs or who developed the T315I mutation after treatment